Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes

QJM: An International Journal of Medicine

Volumn 107, Issue 10, 2014, Pages 821-828

  Makatsori, M ^a   Kiani Alikhan, S ^b   Manson, A L ^c   Verma, N ^d   Leandro, M ^e   Gurugama, N P ^f   Longhurst, H J ^c   Grigoriadou, S ^c   Buckland, M ^c   Kanfer, E ^g   Hanson, S ^f   Ibrahim, M A A ^f   Grimbacher, B ^d,h   Chee, R ^d   Seneviratne, S L ^d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^h UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BRONCHITIS; CAMPYLOBACTER ENTERITIS; CLINICAL ASSESSMENT; CONJUNCTIVITIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; EAR INFECTION; ESOPHAGUS CANDIDIASIS; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MIDDLE AGED; NONHODGKIN LYMPHOMA; OSTEOMYELITIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINUSITIS; SUBSTITUTION THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TETANUS; TREATMENT DURATION; URINARY TRACT INFECTION; VACCINATION; YOUNG ADULT; AUTOIMMUNE DISEASES; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DYSGAMMAGLOBULINEMIA; LYMPHOMA, B-CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; DYSGAMMAGLOBULINEMIA; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB;

EID: 84964314585     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu094     Document Type: Article

References (36)

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164-74.
2. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756-65.
3. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose ranging assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol 2008; 35:20-30.
4. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013; 22:1489-503.
5. Maung SW, Leahy M, O'Leary HM, Khan I, Cahill MR, Gilligan O, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol 2013; 163:118-22.
6. Gómez-Almaguer D. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP). Hematology 2012; 17(Suppl. 1):S25-7.
7. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-73.
8. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121:913-8.
9. Castagnola E, Dallorso S, Faraci M, Morreale G, Di Martino D, Cristina E, et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hematother Stem Cell Res 2003; 12:9-10.
10. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009; 46:120-2.
11. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine 2010; 89:308-18.
12. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4:599-608.
13. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48:1307-12.
14. Le Clech L, Ianotto J-C, Quintin-Roue I, Tempescul A. Severe CMV complication following maintenance therapy with rituximab. BMJ Case Reports, doi: 10.1136/bcr-2012-006672 [Epub 9 January 2013].
15. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-40.
16. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100:2257-9.
17. Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010; 63:275-7.
18. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. J Clin Oncol 1998; 16:2825-33.
19. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Medicine 2011; 9:36.
20. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17:1424-7.
21. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011; 15: e2-16.
22. Taverna CJ, Hitz F, Mingrone W, Pabst T, Cevreska L, del Giglio A, et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. Blood 2010; 116:1802.
23. Arcaini L, Merli M. Rituximab maintenance in follicular lymphoma patients. World J Clin Oncol 2011; 2:281-8.
24. Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009; 50:357-65.
25. Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009; 101:248-55.
26. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006; 20:915-28.
27. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71(Suppl. 2):i2-45.
28. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72:1496-502.
29. Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol, 2006; 77:226-32.
30. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L, et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43:701-8.
31. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13:106-11.
32. de la Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 2012; 51:833-40.
33. Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008; 58:5-14.
34. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75-81.
35. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62:64-74.
36. Mouthon L, Fermand JP, Gottenberg JE. Management of secondary immune deficiencies: what is the role of immunoglobulins? Curr Opin Allergy Clin Immunol 2013; 13(Suppl. 2):S56-67.